<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>

<!-- Mirrored from www.naturesbounty.com/vf/healthnotes/HN_Live/Spanish/Es-Supp/N_Acetyl_Cysteine.ref.htm by HTTrack Website Copier/3.x [XR&CO'2005], Thu, 03 Mar 2005 14:33:45 GMT -->
<head>
<meta http-equiv="Content-Type" content="text/html; charset=ISO-8859-1">
<meta name="Language" content="es">
<meta name="ContentID" content="2888006">
<meta name="Category" content="Supp">
<meta name="Article" content="N_Acetyl_Cysteine">
<title>N-Acetilciste&#237;na-Referencias</title>
<link type="text/css" rel="stylesheet" href="../Styles/hnqrHtml.css">
<base target="_self">
</head>
<body>
<div id="Article-Title" class="Article-Title"><a name="Article-Title"></a> 

<p class="Article-Title">N-Acetilciste&#237;na</p>
</div>

<div id="Reference-List" class="Reference-List">
<p class="Reference-Autofill"><a href="N_Acetyl_Cysteine.htm">Volver al
art&#237;culo.</a></p>

<h3>Referencias para el art&#237;culo</h3>

<ol class="Reference-List">
<li class="Ref">Boman G, B&#228;cker U, Larsson S, et al. Oral acetylcysteine reduces
exacerbation rate in chronic bronchitis: a report of a trial organized by the Swedish Society
for Pulmonary Diseases. <em>Eur J Respir Dis</em> 1983;64:405&#8211;15.</li>

<li class="Ref">Multicenter Study Group. Long-term oral acetylcysteine in chronic bronchitis.
A double-blind controlled study. <em>Eur J Respir Dis</em> 1980;61:111:93&#8211;108.</li>

<li class="Ref">Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term
<em>N</em>-Acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published
double-blind, placebo-controlled clinical trials. <em>Clin Ther
2000</em>;22:209&#8211;21.</li>

<li class="Ref">Van Schayck CP, Dekhuijzen PNR, Gorgels WJMJ, et al. Are anti-oxidant and
anti-inflammatory treatments effective in different subgroups of COPD? A hypothesis. <em>
Respir Med</em> 1998;92:1259&#8211;64.</li>

<li class="Ref">Ben-Ari Z, Vaknin H, Tur-Kaspa R. N-acetylcysteine in acute hepatic failure
(non-paracetamol-induced). <em>Hepatogastroenterology</em> 2000;47:786&#8211;9.</li>

<li class="Ref">Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of
radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. <em>N Engl
J Med</em> 2000;343:180&#8211;4.</li>

<li class="Ref">Estensen RD, Levy M, Klopp SJ, et al. N-acetylcysteine suppression of the
proliferative index in the colon of patients with previous adenomatous colonic polyps. <em>
Cancer Lett</em> 1999;147:109&#8211;14.</li>

<li class="Ref">Hurd RW, Wilder BJ, Helveston WR, Utham BM. Treatment of four siblings with
progressive myoclonus epilepsy of the Unverricht-Lundborg type with <em>N-</em>acetylcysteine.
<em>Neurology</em> 1996;47:1264&#8211;8.</li>

<li class="Ref">Selwa LM. <em>N</em>-Acetylcysteine therapy for Unverricht-Lundborg disease.
<em>Neurology</em> 1999;52:426&#8211;7.</li>

<li class="Ref">Vadoud-Seyedi J, de Dobbeleer G, Simonart T. Treatment of
haemodialysis-associated pseudoporphyria with N-acetylcysteine: report of two cases. <em>Br J
Dermatol</em> 2000;142:580&#8211;1.</li>

<li class="Ref">Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage
in patients with abnormal renal function undergoing a coronary procedure. <em>J Am Coll
Cardiol</em> 2002;40:1383&#8211;8.</li>

<li class="Ref">Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage
in patients with abnormal renal function undergoing a coronary procedure. <em>J Am Coll
Cardiol</em> 2002;40:1383&#8211;8.</li>

<li class="Ref">de Quay B, Malinverni R, Lauterburg BH. Glutathione depletion in HIV-infected
patients: role of cysteine deficiency and effect of oral N-acetylcysteine. <em>AIDS</em>
1992;6:815&#8211;9.</li>

<li class="Ref">Tattersall AB, Bridgman KM, Huitson A. Acetylcysteine (Fabrol) in chronic
bronchitis&#8212;a study in general practice. <em>J Int Med Res</em>
1983;11:279&#8211;84.</li>

<li class="Ref">Kleinveld HA, Demacker PNM, Stalenhoef AFH. Failure of N-acetylcysteine to
reduce low-density lipoprotein oxidizability in healthy subjects. <em>Eur J Clin
Pharmacol</em> 1992;43:639&#8211;42.</li>

<li class="Ref">Brumas V, Hacht B, Filella M, Berthon G. Can N-acetyl-L-cysteine affect zinc
metabolism when used as a paracetamol antidote? <em>Agents Actions</em>
1992;36:278&#8211;88.</li>
</ol>
</div>
</body>

<!-- Mirrored from www.naturesbounty.com/vf/healthnotes/HN_Live/Spanish/Es-Supp/N_Acetyl_Cysteine.ref.htm by HTTrack Website Copier/3.x [XR&CO'2005], Thu, 03 Mar 2005 14:33:45 GMT -->
</html>

